Revuforj (revumenib) [package insert]. FDA.
Regulatory approval published by the Food and Drug Administration.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
Type | Biomarker(s) | Cancer type | Therapy(ies) | |
---|---|---|---|---|
Sensitivity (+) | t(KMT2A;v) | Acute Lymphoid Leukemia | Revumenib | |
Sensitivity (+) | t(KMT2A;v) | Acute Myeloid Leukemia | Revumenib | |
Sensitivity (+) | t(KMT2A;v) | Burkitt Lymphoma | Revumenib | |
Sensitivity (+) | t(KMT2A;v) | Acute Leukemias of Ambiguous Lineage | Revumenib |